On June 30, 2021, Kuramochi, Hidekazu; Yamada, Takeshi; Yoshida, Yoichiro; Matsuda, Akihisa; Kamiyama, Hirohiko; Kosugi, Chihiro; Ishibashi, Keiichiro; Fukazawa, Atsuko; Ihara, Keisuke; Sonoda, Hiromichi; Yoshimatsu, Kazuhiko; Yoshida, Hiroshi; Hasegawa, Suguru; Sakamoto, Kazuhiro; Ishida, Hideyuki; Koda, Keiji; TAS CC3 Study Group published an article.Safety of 5-Methylpyrimidine-2,4(1H,3H)-dione The title of the article was The pre-treatment lymphocyte-to-monocyte ratio predicts efficacy in metastatic colorectal cancer treated with TAS-102 and bevacizumab. And the article contained the following:
Our multicenter phase II TAS-CC3 study demonstrated favorable median progression-free survival (PFS) and overall survival (OS) of 32 metastatic colorectal cancer (mCRC) patients treated with TAS-102 + bevacizumab as 3rd-line treatment. We investigated the predictive and prognostic values of pre-treatment blood inflammation-based scores, including the neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR) and lymphocyte-to-monocyte ratio (LMR) on disease-control (DC), PFS and OS by a post-hoc anal. Receiver operating characteristic curve analyses of the 3 inflammation-based scores vs. DC showed the best predictive performance for LMR, followed by NLR and PLR. The high-LMR group had a significantly higher DC rate than the low group (87.5 vs. 43.8%). The high-LMR group showed significantly longer survival than the low group (4.9 vs. 2.3 m for median PFS) (21.0 vs. 6.1 m for median OS). The pre-treatment LMR is a valid predictive and prognostic biomarker for mCRC patients undergoing TAS-102 and bevacizumab treatment. The experimental process involved the reaction of 5-Methylpyrimidine-2,4(1H,3H)-dione(cas: 65-71-4).Safety of 5-Methylpyrimidine-2,4(1H,3H)-dione
The Article related to tas102 bevacizumab lymphocyte monocyte inflammation colorectal cancer, tas-102, bevacizumab, colorectal cancer, lymphocyte-to-monocyte ratio (lmr), neutrophil-to-lymphocyte ratio (nlr) and other aspects.Safety of 5-Methylpyrimidine-2,4(1H,3H)-dione
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia